Cardiovigilance in COVID 19

J Pak Med Assoc. 2020 May;70(Suppl 3)(5):S77-S80. doi: 10.5455/JPMA.14.

Abstract

The COVID19 (Corona Virus Disease: pandemic started in 2019) pandemic has created not only a public health problem, but as a clinical challenge as well. To the cardiologist, COVID 19 presents a wide spectrum of possibilities for clinical decision-making intervention and improvement. Cardiac dysfunction has been identified as a risk factor, a prognostic factor, a diagnostic tool, differential diagnosis, a complication of COVID 19, and a side effect of its treatment. Certain cardiotropic drugs have been implicated in the pathogenesis of COVID 19. The risk of transmission of COVID 19 is an occupational hazard which cannot be ignored by cardiologists. This review discusses the need and scope of cardio vigilance in COVID 19 management.

Keywords: Cardiovascular, Conduction defects, Coronavirus, Diabetes, Heart failure, Myocarditis..

Publication types

  • Review

MeSH terms

  • Betacoronavirus*
  • COVID-19
  • Clinical Decision-Making
  • Coronavirus Infections* / complications
  • Coronavirus Infections* / diagnosis
  • Coronavirus Infections* / epidemiology
  • Heart Diseases* / complications
  • Heart Diseases* / drug therapy
  • Heart Diseases* / epidemiology
  • Humans
  • Pandemics*
  • Pneumonia, Viral* / complications
  • Pneumonia, Viral* / diagnosis
  • Pneumonia, Viral* / epidemiology
  • Risk Factors
  • SARS-CoV-2